소화기 질환 치료 시장 : 세계 예측(2026-2032년)

The Gastrointestinal Diseases Therapeutics Market is projected to grow by USD 57.71 billion at a CAGR of 4.11% by 2032.

Gastrointestinal Diseases Therapeutics Executive Summary

Gastrointestinal diseases therapeutics are entering a high-priority phase of clinical, regulatory, and commercial attention as digestive disorders continue to affect large patient populations across inflammatory, functional, acid-related, motility, hepatic, pancreatic, infectious, and microbiome-associated conditions. The therapeutic landscape spans biologics, small molecules, antibiotics, acid suppressants, antiemetics, antidiarrheals, laxatives, enzyme replacement therapies, bile acid modulators, immunomodulators, probiotics, and emerging live biotherapeutic and cell-targeted approaches. Demand is being shaped by the rising clinical burden of inflammatory bowel disease, irritable bowel syndrome, gastroesophageal reflux disease, peptic ulcer disease, celiac disease, constipation, diarrhea-associated disorders, and gastrointestinal complications linked to metabolic disease, oncology treatment, aging, and antimicrobial resistance.

The sector is increasingly defined by precision gastroenterology, earlier diagnosis, biomarker-guided treatment selection, patient-reported outcome integration, and a shift from symptom control toward mucosal healing, sustained remission, infection prevention, and quality-of-life improvement. Regulatory agencies continue to emphasize robust clinical endpoints, long-term safety monitoring, pharmacovigilance, and real-world evidence for chronic gastrointestinal therapies. At the same time, healthcare systems are placing greater attention on treatment adherence, affordability, specialty drug access, and reducing hospitalization linked to severe gastrointestinal flare-ups or complications. For industry stakeholders, the strategic opportunity lies in developing differentiated therapies that address unmet needs while aligning with payer expectations, clinical guidelines, antimicrobial stewardship, and digitally enabled care pathways.

Transformative Shifts in the Gastrointestinal Therapeutics Landscape

The gastrointestinal diseases therapeutics landscape is shifting from broad symptom management to targeted, mechanism-driven care. In inflammatory bowel disease, treatment strategies are moving beyond conventional corticosteroids and immunosuppressants toward biologics and oral small molecules that target immune pathways associated with intestinal inflammation. In acid-related disorders, clinicians are balancing the widespread use of proton pump inhibitors and histamine-2 receptor antagonists with growing interest in newer acid suppression mechanisms and improved long-term safety stewardship. Functional gastrointestinal disorders are also evolving as neuromodulation, gut-brain axis science, dietary management, and microbiome-related interventions gain clinical relevance.

A major transformation is the growing role of the gut microbiome as both a therapeutic target and a diagnostic signal. Evidence linking microbial composition to recurrent infection, inflammatory activity, metabolic dysfunction, and treatment response has accelerated research into live biotherapeutics, microbiota restoration, bacteriophage approaches, and microbiome-informed companion diagnostics. Another shift involves the expansion of home-based and decentralized care, including self-administered therapies, remote symptom tracking, virtual gastroenterology consultations, and digital adherence support for chronic conditions such as inflammatory bowel disease and irritable bowel syndrome.

Regulatory expectations are also changing. Authorities increasingly require stronger evidence on sustained response, steroid-free remission, mucosal healing, infection risk, malignancy risk, and post-authorization safety. Payers and health technology assessment bodies are scrutinizing comparative effectiveness, treatment sequencing, and total cost of care, particularly for specialty therapeutics. These changes are encouraging developers to design patient-centric trials, incorporate real-world data, and demonstrate measurable benefits beyond conventional clinical response.

Cumulative Impact of Artificial Intelligence on Gastrointestinal Therapeutics

Artificial intelligence is becoming a practical accelerator across gastrointestinal diseases therapeutics, particularly in drug discovery, clinical trial design, biomarker identification, disease monitoring, and treatment personalization. AI-enabled platforms can analyze multi-omics datasets, endoscopy images, electronic health records, pathology reports, microbiome profiles, and patient-reported outcomes to identify disease subtypes and predict therapeutic response. In inflammatory bowel disease, AI has shown strong potential in supporting endoscopic assessment, detecting mucosal inflammation, and standardizing image interpretation, which may improve trial consistency and clinical decision-making.

AI is also improving research efficiency by identifying eligible trial participants, predicting dropout risk, optimizing site selection, and detecting safety signals from real-world datasets. Natural language processing can extract relevant gastrointestinal symptoms, medication histories, and comorbidities from unstructured clinical notes, helping researchers and clinicians better understand disease trajectories. In pharmacovigilance, AI-based signal detection can support earlier identification of adverse events associated with immunosuppressive agents, biologics, antibiotics, and chronic acid suppression therapies.

The cumulative impact of AI is strongest when integrated with clinical validation, transparent governance, and data privacy safeguards. Gastrointestinal disease datasets are often fragmented across endoscopy centers, pathology laboratories, hospitals, pharmacies, and patient apps, making interoperability and data quality essential. Industry leaders that deploy AI responsibly can improve target discovery, accelerate evidence generation, refine patient stratification, and support value-based care without replacing clinician judgment. The next competitive edge will come from combining AI with biomarker science, real-world evidence, and patient-centered digital health infrastructure.

Key Regional Insights Across Global Gastrointestinal Therapeutics

Asia-Pacific is becoming increasingly important in gastrointestinal diseases therapeutics due to its large patient base, aging demographics in several economies, rising diagnosis of inflammatory bowel disease in urban populations, high prevalence of gastrointestinal infections in parts of the region, and expanding access to specialty care. Countries such as China, India, Japan, South Korea, and Australia are strengthening clinical research capacity, while regional healthcare systems continue to manage the dual burden of infectious gastrointestinal disease and chronic digestive disorders. Improved endoscopy availability, broader insurance coverage in select markets, and growing physician familiarity with biologics, biosimilars, and advanced small molecules are shaping treatment adoption.

North America remains one of the most advanced regions for gastrointestinal therapeutics, supported by established specialty care networks, high diagnostic penetration, broad access to endoscopy, strong use of biologics for inflammatory bowel disease, and extensive real-world evidence generation. The region also demonstrates high awareness of acid-related disorders, irritable bowel syndrome, colorectal screening pathways, and chronic gastrointestinal disease management. Regulatory rigor, payer utilization controls, antimicrobial stewardship, and demand for comparative effectiveness evidence continue to shape therapy access and treatment sequencing.

Latin America presents a heterogeneous but increasingly active environment for gastrointestinal therapeutics. Brazil and Mexico are key centers for diagnosis, clinical practice development, and specialty treatment adoption, while disparities in public and private healthcare access influence treatment continuity. The region continues to manage infectious gastrointestinal conditions, Helicobacter pylori-related disease, inflammatory bowel disease, functional bowel disorders, and liver-associated digestive disorders, creating demand for both affordable essential medicines and advanced therapies.

Europe is characterized by strong clinical guideline adoption, mature gastroenterology networks, advanced inflammatory bowel disease management, and centralized health technology assessment processes. The region places high emphasis on evidence-based prescribing, biosimilar integration, cost-effectiveness, antimicrobial stewardship, and post-marketing safety. Western European countries generally have broader access to advanced therapies, while Central and Eastern European markets continue to expand specialty care infrastructure and reimbursement pathways.

The Middle East is experiencing rising demand for gastrointestinal therapeutics as lifestyle-related disorders, obesity, diabetes, inflammatory bowel disease, and acid-related conditions become more visible in clinical practice. Gulf healthcare systems are investing in tertiary hospitals, specialist training, diagnostic capacity, and access to innovative medicines, while other parts of the region face access variability. Africa faces a complex gastrointestinal disease burden that includes infectious diarrhea, parasitic disease, Helicobacter pylori infection, malnutrition-associated gastrointestinal complications, and an emerging recognition of chronic inflammatory and functional disorders. Access to diagnostics, medicine availability, cold-chain reliability, and healthcare infrastructure remain central determinants of therapeutic outcomes across the continent.

Key Group Insights for Gastrointestinal Diseases Therapeutics

ASEAN countries are witnessing steady advancement in gastrointestinal care as urbanization, dietary shifts, healthcare investment, and better diagnostic access increase recognition of acid-related disorders, inflammatory bowel disease, liver-linked digestive disease, and infectious gastrointestinal conditions. Regional differences in reimbursement, specialist availability, and public health infrastructure influence the pace of advanced therapy adoption, while essential medicines, vaccination where applicable, and antimicrobial stewardship remain core priorities.

The GCC is strengthening its position in digestive disease management through investment in specialist hospitals, digital health, advanced diagnostics, and access to innovative therapies. Rising rates of obesity, diabetes, reflux disease, fatty liver-associated gastrointestinal complications, and immune-mediated disorders are shaping clinical demand. Centralized procurement and national health transformation programs are also influencing formulary decisions, referral pathways, and care standardization.

The European Union represents a highly regulated and evidence-driven environment where gastrointestinal therapeutics are shaped by harmonized medicine authorization, country-level reimbursement assessments, clinical guideline adherence, biosimilar utilization, and pharmacovigilance. The EU's emphasis on real-world evidence, antimicrobial resistance control, cross-border clinical research, and equitable access supports structured adoption of both established and advanced therapies.

BRICS countries combine large patient populations with diverse healthcare systems, making them strategically important for gastrointestinal disease therapeutics. Brazil, Russia, India, China, and South Africa face varying burdens of infectious disease, inflammatory bowel disease, reflux disease, Helicobacter pylori infection, and functional gastrointestinal disorders. Expanding domestic manufacturing, clinical trial participation, public coverage initiatives, and regulatory modernization are influencing access, while affordability remains a defining factor.

G7 countries are among the most mature environments for advanced gastrointestinal therapeutics, with established regulatory systems, high clinical research activity, strong specialist networks, and broad availability of innovative medicines. However, cost containment, evidence thresholds, biosimilar competition, and patient access controls remain prominent. NATO member countries overlap significantly with high-income healthcare systems in North America and Europe, but access patterns vary by national reimbursement policy, defense-related health systems, and public sector procurement practices. Across these groups, the common strategic theme is the need to align innovation with clinical value, affordability, supply resilience, and long-term safety evidence.

Key Country Insights in Gastrointestinal Diseases Therapeutics

The United States leads in advanced gastrointestinal therapeutics adoption, supported by extensive specialist networks, clinical trial infrastructure, strong use of biologics and oral targeted therapies, and sophisticated payer management. Canada emphasizes evidence-based reimbursement, specialist-led inflammatory bowel disease care, and public-private access pathways. Mexico is expanding gastrointestinal diagnosis and treatment availability, though access varies between public and private systems and between urban and non-urban care settings.

Brazil is a major Latin American center for digestive disease care, with growing attention to inflammatory bowel disease, Helicobacter pylori management, reflux disease, infectious gastrointestinal disorders, and advanced therapies in specialized settings. The United Kingdom maintains strong guideline-driven gastroenterology practice, centralized health technology assessment, and structured inflammatory bowel disease care pathways. Germany has a highly developed specialist care system with broad diagnostic access, strong clinical research activity, and established use of biologics and biosimilars. France combines mature reimbursement processes with robust hospital-based gastroenterology networks and emphasis on safety monitoring. Russia faces a broad digestive disease burden with access shaped by regional healthcare capacity, reimbursement policies, and domestic medicine supply considerations. Italy and Spain both have strong gastroenterology expertise, active inflammatory bowel disease care networks, and increasing attention to biosimilar adoption, antimicrobial stewardship, and cost-effective treatment sequencing.

China is rapidly expanding its gastrointestinal therapeutics capabilities through broader hospital infrastructure, increased diagnosis of inflammatory bowel disease, high attention to Helicobacter pylori infection, and growing participation in clinical research. India faces a dual burden of infectious gastrointestinal disease and increasing chronic digestive disorders, with access influenced by affordability, urban-rural disparities, and expanding private healthcare capacity. Japan has advanced diagnostic standards, strong endoscopy utilization, aging-related digestive disease needs, and established use of innovative therapies under strict regulatory and reimbursement controls. Australia supports high-quality gastroenterology care through specialist services, public reimbursement mechanisms, and active management of inflammatory bowel disease and functional gastrointestinal disorders. South Korea combines advanced hospital systems, high endoscopy use, growing specialty medicine adoption, and strong digital health capabilities, making it an important market for evidence-driven gastrointestinal therapeutics.

Actionable Recommendations for Gastrointestinal Therapeutics Leaders

Industry leaders should prioritize differentiated therapeutic development that addresses clear unmet needs in inflammatory bowel disease, functional gastrointestinal disorders, recurrent infection, acid-related disease, motility disorders, and microbiome-mediated conditions. Clinical programs should be designed around meaningful endpoints such as durable remission, mucosal healing, symptom relief, steroid reduction, hospitalization avoidance, infection recurrence reduction, and patient-reported quality-of-life improvement. Incorporating biomarker strategies early can support patient stratification, improve trial efficiency, and strengthen payer-facing evidence.

Organizations should expand real-world evidence capabilities to demonstrate comparative effectiveness, long-term safety, adherence patterns, and total care impact. This is particularly important for biologics, oral targeted agents, chronic acid suppression therapies, antimicrobial regimens, and microbiome-based interventions. Collaboration with gastroenterologists, primary care providers, payers, patient groups, and digital health stakeholders can improve treatment pathway alignment, support earlier diagnosis, and reduce avoidable disease escalation.

To improve global access, leaders should tailor commercialization strategies to regional reimbursement systems, diagnostic infrastructure, and affordability constraints. Biosimilar readiness, patient support programs, supply chain resilience, cold-chain planning, and local regulatory engagement are essential for sustainable access. AI and digital tools should be used to enhance, not replace, clinical decision-making by supporting trial recruitment, adherence monitoring, safety surveillance, and personalized care. Finally, industry stakeholders should invest in antimicrobial stewardship, transparent safety communication, and evidence-based education to build trust among clinicians, payers, and patients.

Research Methodology for Gastrointestinal Therapeutics Intelligence

This executive summary is developed through a structured secondary research approach using verified public-domain and industry-relevant sources, including regulatory guidance, clinical practice guidelines, peer-reviewed medical literature, public health publications, pharmacovigilance resources, health technology assessment frameworks, and disease-specific clinical evidence. The methodology emphasizes triangulation across clinical, regulatory, epidemiological, and healthcare delivery perspectives to ensure balanced interpretation of gastrointestinal diseases therapeutics.

The analysis reviews therapeutic classes, disease burden indicators, treatment pathway evolution, regional healthcare characteristics, reimbursement considerations, innovation trends, and technology-enabled care models. Particular attention is given to inflammatory bowel disease, gastroesophageal reflux disease, irritable bowel syndrome, peptic ulcer disease, infectious gastrointestinal disorders, microbiome-associated conditions, liver-linked digestive disorders, motility disorders, and chronic digestive disease management. Regional, group, and country insights are synthesized qualitatively to reflect differences in diagnostic access, clinical infrastructure, regulatory expectations, payer requirements, and therapy adoption patterns.

The research approach deliberately excludes market sizing, market share analysis, and forecasting. Instead, it focuses on evidence-backed strategic intelligence, clinical relevance, and operational implications for stakeholders involved in gastrointestinal therapeutics development, access, and delivery.

Conclusion: Strategic Outlook for Gastrointestinal Diseases Therapeutics

Gastrointestinal diseases therapeutics are advancing through a period of scientific diversification, clinical precision, and increasing accountability for real-world value. The field is expanding from conventional symptom management to targeted immunology, microbiome science, biomarker-guided care, advanced acid suppression, digital monitoring, and AI-enabled research. Across regions, adoption is shaped by disease burden, diagnostic infrastructure, reimbursement policy, specialist availability, affordability, and long-term safety expectations.

The most resilient strategies will be those that combine differentiated mechanisms of action with strong safety evidence, patient-centered outcomes, scalable access models, and measurable healthcare system value. As chronic digestive disorders and infectious gastrointestinal conditions continue to place pressure on healthcare systems, stakeholders that align innovation with clinical evidence, responsible AI use, antimicrobial stewardship, and equitable access will be best positioned to support improved outcomes in gastrointestinal diseases therapeutics.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Gastrointestinal Diseases Therapeutics Market, by Indication

• 7.1. Introduction
• 7.2. Acid-Related Disorders
  • 7.2.1. Dyspepsia
  • 7.2.2. Gastroesophageal Reflux Disease
  • 7.2.3. Peptic Ulcer Disease
• 7.3. Infectious Gastroenteritis
  • 7.3.1. Bacterial Gastroenteritis
  • 7.3.2. Parasitic Infections
  • 7.3.3. Viral Gastroenteritis
• 7.4. Inflammatory Bowel Disease
  • 7.4.1. Crohn's Disease
  • 7.4.2. Ulcerative Colitis
• 7.5. Irritable Bowel Syndrome
  • 7.5.1. Constipation-Predominant
  • 7.5.2. Diarrhea-Predominant
  • 7.5.3. Mixed Type

8. Gastrointestinal Diseases Therapeutics Market, by Drug Class

• 8.1. Introduction
• 8.2. Aminosalicylates
• 8.3. Antibiotics
  • 8.3.1. Ciprofloxacin
  • 8.3.2. Metronidazole
  • 8.3.3. Rifaximin
• 8.4. Antidiarrheals
• 8.5. Antispasmodics
• 8.6. Biologics
  • 8.6.1. Anti Integrin Agents
  • 8.6.2. Anti Tumor Necrosis Factor Agents
  • 8.6.3. Interleukin Inhibitors
• 8.7. H2 Receptor Antagonists
• 8.8. Laxatives
• 8.9. Proton Pump Inhibitors

9. Gastrointestinal Diseases Therapeutics Market, by Route Of Administration

• 9.1. Introduction
• 9.2. Oral
• 9.3. Parenteral
• 9.4. Topical

10. Gastrointestinal Diseases Therapeutics Market, by Dosage Form

• 10.1. Introduction
• 10.2. Powder
• 10.3. Suspension
• 10.4. Tablet/Capsule

11. Gastrointestinal Diseases Therapeutics Market, by End User

• 11.1. Introduction
• 11.2. Clinic
• 11.3. Home Healthcare
• 11.4. Hospital

12. Gastrointestinal Diseases Therapeutics Market, by Distribution Channel

• 12.1. Introduction
• 12.2. Offline
• 12.3. Online

13. Gastrointestinal Diseases Therapeutics Market, by Region

• 13.1. Asia-Pacific
• 13.2. North America
• 13.3. Latin America
• 13.4. Europe
• 13.5. Middle East
• 13.6. Africa

14. Gastrointestinal Diseases Therapeutics Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Gastrointestinal Diseases Therapeutics Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2025
• 16.2. FPNV Positioning Matrix, 2025
• 16.3. Market Concentration Analysis, 2025
  • 16.3.1. Concentration Ratio (CR)
  • 16.3.2. Herfindahl Hirschman Index (HHI)
• 16.4. Recent Developments & Impact Analysis, 2025
• 16.5. Product Portfolio Analysis, 2025
• 16.6. Benchmarking Analysis, 2025

17. Company Profiles

• 17.1. Abbott Laboratories
• 17.2. AbbVie Inc.
• 17.3. Amgen Inc.
• 17.4. AstraZeneca PLC
• 17.5. Bausch Health Companies Inc.
• 17.6. Bayer AG
• 17.7. Biogen Inc.
• 17.8. Boehringer Ingelheim International GmbH
• 17.9. Bristol-Myers Squibb Company
• 17.10. Cipla Limited
• 17.11. Dr. Reddy's Laboratories Ltd.
• 17.12. Eli Lilly and Company
• 17.13. F. Hoffmann-La Roche Ltd
• 17.14. Ferring B.V.
• 17.15. Gilead Sciences, Inc.
• 17.16. GSK plc
• 17.17. Johnson & Johnson Services Inc.
• 17.18. Merck & Co., Inc.
• 17.19. Novartis AG
• 17.20. Novo Nordisk A/S
• 17.21. Organon & Co.
• 17.22. Pfizer Inc.
• 17.23. Sanofi S.A.
• 17.24. Sun Pharmaceutical Industries Limited
• 17.25. Takeda Pharmaceutical Company Limited
• 17.26. Teva Pharmaceutical Industries Ltd.
• 17.27. UCB SA
• 17.28. Viatris Inc.